Clinical Trial Update: A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg for Long-term Use to Prevent Recurrence of Atrial Fibrillation/Flutter After Terminating Its Persistent Form [Phase 2]

View source ↗

Summary

Phase 2 trial update describing dose selection and evaluation of the effectiveness and safety of Refralon tablets (1 mg) for long-term prevention of atrial fibr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Atrial Flutter

Drugs mentioned

• Refralon

Snippet

Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation | Conditions: Atrial Fibrillation, Atrial Flutter | Phase 2 | Status: ACTIVE_NOT_RECRUITING